We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01179295
Previous Study | Return to List | Next Study

Japanese BAY86-9766 Monotherapy Phase I Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01179295
Recruitment Status : Completed
First Posted : August 11, 2010
Last Update Posted : June 20, 2017
Information provided by (Responsible Party):

Brief Summary:
This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles in Japanese patients with advanced solid tumors

Condition or disease Intervention/treatment Phase
Neoplasms Drug: BAY86-9766 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Single Agent BAY86-9766 in Japanese Patients With Advanced or Refractory Solid Tumors
Actual Study Start Date : November 19, 2010
Actual Primary Completion Date : April 27, 2012
Actual Study Completion Date : April 27, 2012

Arm Intervention/treatment
Experimental: Arm 1 Drug: BAY86-9766
BAY86-9766 30 mg twice a day (bid).

Experimental: Arm 2 Drug: BAY86-9766
BAY86-9766 50 mg twice a day (bid).

Experimental: Arm 3 Drug: BAY86-9766
BAY86-9766 100 mg once a day (od)

Experimental: Arm 4 Drug: BAY86-9766
BAY86-9766 60 mg once a day (od)

Primary Outcome Measures :
  1. Safety evaluation due to results of physical examinations, vital signs, AEs, abnormal laboratory tests and 12-lead ECG, cardiac function test and ophthalmological examination. [ Time Frame: At the end of 30-day follow up after discontinuation of study drug administration ]
  2. Calculation of pharmacokinetic parameters of BAY86-9766 and its metabolite (M17). [ Time Frame: Cycle 1 Day 22 and Day 23 for Cohorts 1 & 2 and Cohorts 3 & 4, respectively. ]

Secondary Outcome Measures :
  1. Response rate [ Time Frame: On average 3 months ]
  2. Disease control rate [ Time Frame: On average 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Japanese patients, who are at least 18 years of age at the first screening examination/ visit, with advanced or refractory solid tumors not amenable to standard therapy.
  • Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, with no current involvement in the central nervous system (CNS)
  • At least one measurable lesion or evaluable disease according to response evaluation criteria in solid tumors (RECIST) version 1.1
  • Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1
  • Life expectancy of at least 12 weeks

Exclusion Criteria:

  • Use of any anti-cancer therapy including chemotherapy, investigational agents or devices and immunotherapy within 4 weeks of the first dose of study medication
  • Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
  • Known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C
  • Inadequate bone marrow, liver and renal function
  • Inability to swallow oral medications or any condition that could affect the absorption of orally administered drugs
  • Concomitant treatment with cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers, and CYP2C19 inhibitors/ inducers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01179295

Layout table for location information
Kashiwa, Chiba, Japan, 277-8577
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01179295    
Other Study ID Numbers: 15091
First Posted: August 11, 2010    Key Record Dates
Last Update Posted: June 20, 2017
Last Verified: June 2017
Keywords provided by Bayer:
MEK inhibitor
RDEA 119
Solid tumor